Eli Lilly and Co. was issued a complete response letter from the U.S. FDA for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema). The letter cited findings from a multi-sponsor inspection of a third-party, contract manufacturing organization that included the monoclonal antibody drug substance for Lilly’s lebrikizumab.   The letter stated no concerns about the clinical data package, safety or label for lebrikizumab. No o...